Routine use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) is recommended in proteinuric nontransplant kidney disease patients, to reduce proteinuria and ...
In addition to their capacity to lower systemic blood pressure, angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-II receptor blockers (ARBs) are thought to have specific ...
According to the editorialists, these results trump prior results and should lead to elimination of ACE-I or ARB use for preserving kidney function in normotensive type 1 diabetic patients with ...
Patients received daily enalapril (an angiotensin-converting–enzyme inhibitor [ACE-I]; 20 mg), losartan ... as measured by renal biopsy) and retinopathy (progression of ≥2 steps on a ...
The global IgA Nephropathy Disease Treatment Market is at the forefront of addressing the growing burden of renal diseases worldwide. With a projected value surpassing USD 485 million by 2028, the ...
This medication is an angiotensin-converting enzyme inhibitor (ACE inhibitor), prescribed for high blood pressure (hypertension), congestive heart failure, myocardial infarction and kidney ...